Related Experiment Videos
[Experience with prostate-specific antigen in patients with prostatic cancer]
Orvosi Hetilap
|December 24, 1989
Summary
Prostatic specific antigen (PSA) shows higher pathological concentrations in prostate cancer patients compared to other markers. PSA levels effectively monitor treatment response, suggesting its increased clinical use for prostate cancer management.
Area of Science:
- Urology
- Oncology
- Biochemistry
Context:
- Investigated serum concentrations of prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in 71 prostate cancer patients and 45 benign prostatic hyperplasia (BPH) patients.
- Compared radio-immunoassay and enzymatic methods for enzyme determination.
Purpose:
- To evaluate the diagnostic and monitoring utility of PSA and PAP in prostate cancer.
- To compare the efficacy of PSA and PAP in detecting prostate cancer across different stages.
Summary:
- Untreated prostate cancer patients exhibited higher pathological serum PSA concentrations across all stages compared to PAP, SPP, and SP.
- Serum PSA and PAP levels demonstrated a clear decrease following therapy initiation, highlighting PSA's monitoring capability.
- Case studies corroborated the effectiveness of PSA in tracking treatment progress.
Impact:
- Suggests increased utilization of PSA determination in routine clinical practice for prostate cancer management.
- Highlights PSA as a valuable biomarker for both diagnosis and treatment monitoring in prostate cancer.
- Emphasizes the superior sensitivity of PSA over PAP in detecting prostate cancer.